IP Library Granted Patent US 6,855,535
Granted Patent B2
US 6,855,535 · App. 10/006,882 · Granted Feb 15, 2005

Method of large scale production of Hepatitis A virus

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,855,535
App. No.
10/006,882
Granted
Feb 15, 2005
Kind
B2
Abstract

The present invention provides methods of large scale production of Hepatitis A Virus (HAV) on VERO cells bound to microcarrier. The invention also provides for methods of isolation of HAV from the cell culture supernatant of HAV infected VERO cells.

Claims (13)

1. A method for continuous production of Hepatitis A virus (HAV) antigen, comprising the steps of providing a serum free cell culture of VERO cells bound to a microcarrier; growing the VERO cells in said serum free cell culture; infecting said serum free cell culture of VERO cells with HAV at a reduced temperature compared to the step of growing the cells; incubating said serum free cell culture of VERO cells infected with HAV to propagate said HAV at the reduced temperature, whereby HAV antigen is continuously released into the cell culture medium because infected cells release at least 50% of viral antigen into said medium; and harvesting said HAV antigen released into said medium.

2. The method according to claim 1 , wherein said cells are grown at a temperature of about 37° C.

3. The method according to claim 1 , wherein said temperature is reduced to about 34° C. prior to infection.

4. The method of claim 1 , wherein the microcarrier is selected from the group of spherical or porous microcarriers.

5. The method according to claim 4 , wherein the microcarriers comprise dextran, gelatine, collagen, plastic, or cellulose.

6. The method according to claim 1 , wherein the cells are infected with HAV at a multiplicity of infection between about 0.01 and about 5.0.

7. The method according to claim 1 , wherein the cell culture is subcultured from a working cell bank and passaged by use of a microbial protease or a trypsin-like enzyme of a microbial origin.

8. The method according to claim 7 , wherein said microbial protease is the trypsin-like enzyme of Streptomyces griseus Pronase.

9. The method according to claim 1 , wherein the cells bound to the microcarrier continuously produce and release HAV antigen into the cell culture medium for at least 60 days.

10. The method according to claim 1 , wherein said serum free cell culture of VERO cells is a serum and protein free cell culture of VERO cells.

11. The method of claim 1 , wherein the HAV antigen released into said medium is a complete HAV particle.

12. The method of claim 11 , further comprising isolating the complete HAV particle from the HAV harvest.

13. The method of claim 12 , wherein the complete HAV particle is isolated by isopycnic centrifugation.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2004
From: BAXTER VACCINE AKTIENGESELLSCHAFT
To: BAXTER HEALTHCARE S.A.
Reel/Frame 014665/0017 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2002
From: MEYER, HEIDI; REITER, MANFRED; MUNDT, WOLFGANG; BARRETT, NOEL; DORNER, FRIEDRICH
To: BAXTER VACCINE AKTIENGESELLSCHAFT
Reel/Frame 012392/0768 →